BioNTech Results Presentation Deck
Outlook for 2H 2020
27
Platform
Fix Vac
iNeST
Intratumoral Immunotherapy
CAR-T Cells
Neoantigen-based T cell therapy
Next-Gen CP Immunomodulators
Infectious Diseases
Candidate
BNT111
BNT113
BNT114
●
RO7198457
(BNT122)
SAR441000
(BNT131)
BNT211
BNT221
(NEO-PTC-01)
BNT311
BNT162
Indication (Target)
advanced melanoma
HPV16+ H&N cancer
triple negative breast cancer
1L melanoma with CPI
NSCLC (adjuvant)
CRC (adjuvant)
Solid tumors
(IL-12sc, IL-15sushi, GM-CSF, IFN a)
multiple solid tumors (CLDN6)
multiple solid tumors
multiple solid tumors (PD-L1x4-1BB)
COVID-19
Next Expected Milestones ³
Start Phase 2 with in 2H 2020
Start Phase 2 with in 2H 2020
Data update Phase 1 in 2H 20204
Enrollment update in 2H 2020¹
Start Phase 2 in 2H 2020
Start Phase 2 in 2H 2020
Data update Phase 1/2 in 2H 2020²
Start Phase 1/2 in 2H 2020
Start Phase 1 in 2H 2020
Data update Phase 1/2 in 2H 2020
Data update Phase 1 (BNT162b2) in Q3 2020
Data update Phase 2/3 in Q4 2020
Expected news flow / milestones:
Phase 1 data for BNT162b2 COVID-19 vaccine and update from Phase 2b/3 trial as early as October 2020
Data updates for 3 oncology trials (BNT114, 131, and 311)
To initiate up to 4 randomized phase 2 trials for FixVac and iNeST
To initiate up to 2 first-in-human phase 1 trials for our Engineered Cell Therapy product candidates
1 We expect this update to include an update on the ongoing study, including patient enrollment numbers, with full efficacy and safety data for an interim update expected in the second half of 2021; 2As the trial is sponsored and
conducted by Sanofi, the timing of data updates is not under our control, and is subject to change by Sanofi. ³Our expectations for timing of milestones beyond 2020 are premised on and subject to the achievement of earlier
milestones on their expected timelines. Press releases will be issued once first patient has been dosed; 4BNT122 (iNeST) is also being investigated in arm 2 (N=15) of the 3 arm TNBC-MERIT trial, with BNT114 as an optional BIONTECH
treatment; BNT114 is investigated in arm 1 (N=12) and arm 3 (N=15) of the TNBC-MERIT trial (total patients in study: N=42);
1
I
I
I
I
I
1
I
I
I
I
I
IView entire presentation